Pioneering designs for recombinant coagulation factors.

@article{Schulte2011PioneeringDF,
  title={Pioneering designs for recombinant coagulation factors.},
  author={Stefan Schulte},
  journal={Thrombosis research},
  year={2011},
  volume={128 Suppl 1},
  pages={
          S9-12
        }
}
Coagulation factor replacement therapy has become an established part of the prevention and treatment of bleeding episodes in patients with bleeding disorders, such as hemophilia A, hemophilia B, and von Willebrand disease. Advances in recombinant DNA technology have made it possible to modify recombinant coagulation factor products to enhance their pharmacokinetic properties, biological activity, or other characteristics. CSL Behring has created two novel albumin fusion proteins with the goal… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Efficacy and safety results of albinterferon alfa - 2 b in combination with ribavirin in interferon - alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C

S Zeuzem, MS Sulkowski, +3 authors BR Bacon
  • J Hepatol
  • 2009

Fusion-proteins as biopharmaceuticals--applications and challenges.

  • Current opinion in drug discovery & development
  • 2009
VIEW 1 EXCERPT

Similar Papers